Evidence map›Paper›PMID 38545437›Full record

ArticlemicroPublication biology2024

The tyrosine kinase inhibitor Gefitinib reduces

Caroline Coto, Adrian Arimie, Jesse G Jones, Cheryl Van Buskirk

Open access · greenAbstract read
In one paragraph

Article in microPublication biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Caroline Coto *Biology, California State University, Northridge.
Adrian Arimie *Biology, California State University, Northridge.
Jesse G JonesBiology, California State University, Northridge.
Cheryl Van BuskirkBiology, California State University, Northridge.
California State University, Northridge · US

Funding

Exploring the function and shedding of a potential C. elegans NeuregulinR16NS134541 · NINDS · CALIFORNIA STATE UNIVERSITY NORTHRIDGE · PI CHERYL LYNN VAN BUSKIRK · 2023 to 2026
$590k
NINDS NIH HHS R16 NS134541
6 · The paper itself

Abstract

The anticancer drug Gefitinib is a tyrosine kinase inhibitor with selectivity for the Epidermal Growth Factor Receptor (EGFR/ErbB1). As the

Identifiers

PMID38545437
PMCPMC10966387
OpenAlexW4394767639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.